Experienced in Chronic Graft Versus Host Disease (cGvHD)

Dr. Morie A. Gertz

Hematology | Oncology
200 1st St Sw, 
Rochester, MN 
Accepting New Patients
Offers Telehealth
43 Years of Experience
Experienced in Chronic Graft Versus Host Disease (cGvHD)
200 1st St Sw, 
Rochester, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Morie Gertz is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Gertz has been practicing medicine for over 43 years and is rated as an Experienced provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Primary Amyloidosis, Multiple Myeloma, Waldenstrom Macroglobulinemia, Bone Marrow Transplant, and Tissue Biopsy. Dr. Gertz is currently accepting new patients.

His clinical research consists of co-authoring 732 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Chronic Graft Versus Host Disease (cGvHD).

Specialties
Hematology
Oncology
Licenses
Internal Medicine in MN
Hospital Affiliations
Mayo Clinic Hospital Rochester
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

MAYO CLINIC
200 1st St Sw, Rochester, MN 55905

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Intravenous ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA)
A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Intravenous ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA)
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Drug
Study Drug: ANX005
Study Phase: Phase 2
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 22, 2023
Intervention Type: Drug
Study Drugs: AO-176, AO-176 + Dex, AO-176 + Dex + Bort
Study Phase: Phase 1/Phase 2
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

732 Total Publications

Unravelling the myriad physiologic roles of transthyretin: critical considerations for treating transthyretin amyloidosis.
Unravelling the myriad physiologic roles of transthyretin: critical considerations for treating transthyretin amyloidosis.
Journal: Annals of medicine
Published: July 28, 2025
Similar Doctors
Elite in Chronic Graft Versus Host Disease (cGvHD)
Dr. Shahrukh K. Hashmi
Hematology
Elite in Chronic Graft Versus Host Disease (cGvHD)
Dr. Shahrukh K. Hashmi
Hematology
200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shahrukh Hashmi is a Hematologist in Rochester, Minnesota. Dr. Hashmi is rated as a Distinguished provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Bone Graft. Dr. Hashmi is currently accepting new patients.

Elite in Chronic Graft Versus Host Disease (cGvHD)
Dr. Mark R. Litzow
Hematology | Hematology Oncology
Elite in Chronic Graft Versus Host Disease (cGvHD)
Dr. Mark R. Litzow
Hematology | Hematology Oncology
200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Litzow is a Hematologist and a Hematologist Oncology provider in Rochester, Minnesota. Dr. Litzow is rated as an Elite provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Graft. Dr. Litzow is currently accepting new patients.

Distinguished in Chronic Graft Versus Host Disease (cGvHD)
Dr. Hassan B. Alkhateeb
Hematology Oncology | Hematology | Oncology
Distinguished in Chronic Graft Versus Host Disease (cGvHD)
Dr. Hassan B. Alkhateeb
Hematology Oncology | Hematology | Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Experience:
17+ years
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Hassan Alkhateeb is a Hematologist Oncology specialist and a Hematologist in Rochester, Minnesota. Dr. Alkhateeb has been practicing medicine for over 17 years and is rated as an Elite provider by MediFind in the treatment of Chronic Graft Versus Host Disease (cGvHD). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Alkhateeb is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gertz's expertise for a condition
ConditionClose
View All 12 Elite Conditions
    View All 12 Advanced Conditions
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile